…Parkinson’s disease An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. Stem cell therapy shows promise in…

…shredding,” the researchers at Gladstone Institutes programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumour cells – and then obliterate those cells by snipping away at…

Scientists at the University of Bath have developed a way of joining up the head and tail of a protein, making it more stable and easier to get into cells….

…neural stem cells directly into the brains of 15 patients with secondary progressive MS. The stem cells are thought to reduce the inflammation that drives the disease. In MS, the…

…recognised that mitochondrial dysfunction is a key driver of PD mechanisms, in particular, playing an important role in the degeneration of brain cells that produce dopamine. By inhibiting the enzyme…

Biotechnology company bit.bio has launched a range of immune cells to provide researchers with a consistently functional and rapid human in vitro model for the study of neuroinflammation and neurodegenerative…

…in cardiac cells. Structural modifications were made to the original molecule to develop AD-9308, which activated the enzyme ALDH2 three times more than the original molecule. Several studies conducted at…

…other indications including choroideremia and Stargardt’s disease.” Conferring light-sensing capabilities KIO-301 can potentially confer light-sensing capabilities to retinal neurons called retinal ganglion cells (RGCs). Once inside the cell, KIO-301 localises…

…positive granzyme B positive cytotoxic T cells, dendritic cells, and B cells, were observed in PDAC tissue after CAN-2409 treatment, confirming activation of a robust antitumoral immune response. “Given frequent…

…venture capital/investor ecosystem to create therapies to vastly extend the healthy human lifespan. In addition to presentations from CEOs of startups in the fields of rejuvenation & longevity, the summit…

…do, but also B cells and dendritic cells.” The Phase I/II trial is a multicentre, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of NDI-101150 given…

…age group. This study, funded by the Medical Research Council, will test the responses of cells in lymph nodes before and after immunisation with flu and Covid-19 vaccines and compare…

…a sample, is an excellent method to generate highly multidimensional functional readouts from biological material, thus giving a precise view on the state of cells and organs, while being highly…

…and Huntington’s disease as well as certain types of dementia. ioCells products are reprogrammed from human induced pluripotent stem cells (iPSCs) by opti-ox, bit.bio’s precision cell programming technology. Mark Kotter,…

…barrier that protects tumours and reversing immunosuppressive mechanisms encouraging the immune system to mount an attack against cancer cells.” Catherine Pickering, Chief Executive Officer of iOnctura, said: “These data support…

…conducted at the University of Minnesota.” NAM technology The NK cells which comprise GDA-201 use Gamida Cell’s NAM technology, which is designed to enhance and expand cells to enhance functionality…